Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medical Research Council | OTHER_GOV |
| GlaxoSmithKline | INDUSTRY |
| CRAFT Consortium | UNKNOWN |
| McMaster University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall aim of this study is to develop a test that predicts the prognosis of IPF (Idiopathic Pulmonary Fibrosis) and which could be used to determine whether new treatments for IPF are likely to work.
The overall objectives of this study are
Biomarkers that can be used for the following purposes will be identified:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Idiopathic pulmonary fibrosis (IPF) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Discover biomarkers in IPF |
| 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Survival from Pulmonary fibrosis. | All patients will be tagged at the central NHS registry in order to provide mortality data. For this reason we will need to keep our datasets active for up to 10 years to allow a complete mortality analysis. | 10 years |
Not provided
Inclusion Criteria:
A diagnosis of IPF using the consensus criteria (32)and Non Specific Interstitial Pneumonia.
Exclusion Criteria:
Not provided
Not provided
Participants will be recruited from IPF clinics
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gisli Jenkins, Dr | University of Nottingham | Study Director |
| Robert Berg, Dr | University Hospitals of Derby and Burton NHS Foundation Trust | Principal Investigator |
| Sanjay Agarwal, Dr | University Hospitals, Leicester | Principal Investigator |
| Moira White, Dr | Sheffield Teaching Hospitals NHS Foundation Trust | Principal Investigator |
| Khaled Amsha, Dr | Sherwood Forest Hospitals NHS Trust | Principal Investigator |
| David Thickett, Dr | University Hospital Birmingham NHS Foundation Trust | Principal Investigator |
| Uttam Nanda, Dr | Burton Hospitals NHS Foundation Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nottingham University Hospitals NHS Trust | Nottingham | NG5 1PB | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35688625 | Derived | Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, Flores C, Noth I, Yaspan BL, Jenkins RG, Wain LV; International IPF Genetics Consortium. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax. 2022 Aug;77(8):829-833. doi: 10.1136/thoraxjnl-2021-218577. Epub 2022 Jun 10. | |
| 34675050 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054990 | Idiopathic Pulmonary Fibrosis |
| D011658 | Pulmonary Fibrosis |
| ID | Term |
|---|---|
| D017563 | Lung Diseases, Interstitial |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D005355 | Fibrosis |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Blood(serum, plasma) & Lavage Fluid
| Derived |
| Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C, Maher TM, Navaratnam V, Hubbard R, Hopkins PMA, Reynolds PN, Chapman S, Zappala C, Keir GJ, Cooper WA, Mahar AM, Ellis S, Goh NS, De Jong E, Cha L, Tan DBA, Leigh L, Oldmeadow C, Walters EH, Jenkins RG, Moodley Y. Biomarker signatures for progressive idiopathic pulmonary fibrosis. Eur Respir J. 2022 Mar 31;59(3):2101181. doi: 10.1183/13993003.01181-2021. Print 2022 Mar. |
| 29150411 | Derived | Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14. |
| 25770676 | Derived | Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R, Molyneaux PL, McKeever TM, Wells AU, Flynn A, Hubbard RB, Leeming DJ, Marshall RP, Karsdal MA, Lukey PT, Maher TM. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med. 2015 Jun;3(6):462-72. doi: 10.1016/S2213-2600(15)00048-X. Epub 2015 Mar 12. |
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |